UY35499A - Indazoles sustituidos con diaminoheteroarilo - Google Patents
Indazoles sustituidos con diaminoheteroariloInfo
- Publication number
- UY35499A UY35499A UY0001035499A UY35499A UY35499A UY 35499 A UY35499 A UY 35499A UY 0001035499 A UY0001035499 A UY 0001035499A UY 35499 A UY35499 A UY 35499A UY 35499 A UY35499 A UY 35499A
- Authority
- UY
- Uruguay
- Prior art keywords
- diaminoheteroarilo
- indazols
- replaced
- drugs
- compounds
- Prior art date
Links
- 101100326430 Caenorhabditis elegans bub-1 gene Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13160350 | 2013-03-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35499A true UY35499A (es) | 2014-10-31 |
Family
ID=47900948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001035499A UY35499A (es) | 2013-03-21 | 2014-03-24 | Indazoles sustituidos con diaminoheteroarilo |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20160052912A1 (enExample) |
| EP (1) | EP2976334A1 (enExample) |
| JP (1) | JP2016514717A (enExample) |
| CN (1) | CN105051030A (enExample) |
| AR (1) | AR095708A1 (enExample) |
| CA (1) | CA2907730A1 (enExample) |
| HK (1) | HK1217324A1 (enExample) |
| TW (1) | TW201514167A (enExample) |
| UY (1) | UY35499A (enExample) |
| WO (1) | WO2014147144A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CN104125957B (zh) | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| US20160046604A1 (en) * | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| WO2014202590A1 (en) | 2013-06-21 | 2014-12-24 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| US9745285B2 (en) | 2013-06-21 | 2017-08-29 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| CN105764893A (zh) | 2013-10-30 | 2016-07-13 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| TW201613886A (en) | 2014-06-17 | 2016-04-16 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones |
| WO2016042084A1 (en) | 2014-09-19 | 2016-03-24 | Bayer Pharma Aktiengesellschaft | Benzyl substituted indazoles as bub1 inhibitors |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| KR102615821B1 (ko) | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999066051A2 (en) * | 1998-06-16 | 1999-12-23 | Sugen, Inc. | Nek-related and bub1-related protein kinases |
| US7378532B2 (en) * | 2004-03-26 | 2008-05-27 | Yung Shin Pharmaceutical Ind. Co., Ltd. | Fused pyrazolyl compound |
| JP2010111624A (ja) * | 2008-11-06 | 2010-05-20 | Shionogi & Co Ltd | Ｔｔｋ阻害作用を有するインダゾール誘導体 |
| CA2756067A1 (en) * | 2009-03-27 | 2010-09-30 | Pathway Therapeutics, Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| CN104125957B (zh) * | 2011-12-21 | 2016-05-25 | 拜耳知识产权有限责任公司 | 取代的苄基吡唑 |
| EP2847180B1 (en) * | 2012-05-11 | 2017-01-04 | Bayer Pharma Aktiengesellschaft | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
| US20160046604A1 (en) * | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted indazoles |
| EP2976336A1 (en) * | 2013-03-21 | 2016-01-27 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
-
2014
- 2014-03-19 CA CA2907730A patent/CA2907730A1/en not_active Abandoned
- 2014-03-19 CN CN201480017090.3A patent/CN105051030A/zh active Pending
- 2014-03-19 EP EP14710931.8A patent/EP2976334A1/en not_active Withdrawn
- 2014-03-19 US US14/778,604 patent/US20160052912A1/en not_active Abandoned
- 2014-03-19 WO PCT/EP2014/055540 patent/WO2014147144A1/en not_active Ceased
- 2014-03-19 HK HK16105232.9A patent/HK1217324A1/zh unknown
- 2014-03-19 JP JP2016503655A patent/JP2016514717A/ja active Pending
- 2014-03-21 TW TW103110771A patent/TW201514167A/zh unknown
- 2014-03-21 AR ARP140101321A patent/AR095708A1/es unknown
- 2014-03-24 UY UY0001035499A patent/UY35499A/es not_active Application Discontinuation
-
2017
- 2017-03-28 US US15/471,885 patent/US20170283396A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TW201514167A (zh) | 2015-04-16 |
| WO2014147144A1 (en) | 2014-09-25 |
| CA2907730A1 (en) | 2014-09-25 |
| US20170283396A1 (en) | 2017-10-05 |
| CN105051030A (zh) | 2015-11-11 |
| US20160052912A1 (en) | 2016-02-25 |
| AR095708A1 (es) | 2015-11-04 |
| JP2016514717A (ja) | 2016-05-23 |
| HK1217324A1 (zh) | 2017-01-06 |
| EP2976334A1 (en) | 2016-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35500A (es) | Indazoles sustituidos con heteroarilo | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| UY36175A (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| ECSP14013284A (es) | Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas | |
| CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
| SV2017005487A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| UY35467A (es) | Compuestos orgánicos | |
| CL2016000925A1 (es) | Inhibidores de bromodominio | |
| CL2016000922A1 (es) | Derivados de anillo bicíclico fusionado piridilo como inhibidores fgfr4 | |
| BR112016012146A8 (pt) | derivados de aminopiridina como inibidores de quinase da família tam | |
| CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
| TR201811764T4 (tr) | Kinaz inhibitörleri olarak aminoheteroaril benzamidleri. | |
| UA116920C2 (uk) | Інгібітори fgfr4 | |
| CL2015003280A1 (es) | Derivados de benzimidazol como inhibidores de bromodominio | |
| MX2015011514A (es) | Compuestos de heteroarilo y sus usos. | |
| CR20150524A (es) | Compuestos de heteroarilo y sus usos | |
| ECSP14033037A (es) | Síntesis de compuestos heterocíclicos | |
| CR20150462A (es) | Inhibidores de erk y sus usos | |
| MX2021001231A (es) | Compuestos heterociclicos y sus usos. | |
| AR095075A1 (es) | Acoplamiento electroquímico de anilinas | |
| EA201500801A1 (ru) | Бензохинолоновые ингибиторы vmat2 | |
| BR112015019624A2 (pt) | quinazolinas como inibidores de quinase | |
| MX2014015039A (es) | Inhibidores de fbx03. | |
| MX373636B (es) | Compuestos de azetidiniloxifenilpirrolidina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20211206 |